Logo image of BDMD

BAIRD MEDICAL INVESTMENT HOL (BDMD) Stock Fundamental Analysis

USA - NASDAQ:BDMD - KYG0705H1039 - Common Stock

2.45 USD
-0.05 (-2%)
Last: 9/12/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, BDMD scores 3 out of 10 in our fundamental rating. BDMD was compared to 191 industry peers in the Health Care Equipment & Supplies industry. BDMD has only an average score on both its financial health and profitability. BDMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year BDMD was profitable.
In the past year BDMD has reported a negative cash flow from operations.
In multiple years BDMD reported negative net income over the last 5 years.
In the past 5 years BDMD always reported negative operating cash flow.
BDMD Yearly Net Income VS EBIT VS OCF VS FCFBDMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

1.2 Ratios

BDMD has a Return On Assets of 16.04%. This is amongst the best in the industry. BDMD outperforms 96.34% of its industry peers.
With an excellent Return On Equity value of 31.53%, BDMD belongs to the best of the industry, outperforming 98.43% of the companies in the same industry.
BDMD's Return On Invested Capital of 22.61% is amongst the best of the industry. BDMD outperforms 98.95% of its industry peers.
Industry RankSector Rank
ROA 16.04%
ROE 31.53%
ROIC 22.61%
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDMD Yearly ROA, ROE, ROICBDMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

BDMD has a better Profit Margin (33.76%) than 97.38% of its industry peers.
BDMD has a better Operating Margin (41.35%) than 100.00% of its industry peers.
BDMD has a better Gross Margin (88.17%) than 97.38% of its industry peers.
Industry RankSector Rank
OM 41.35%
PM (TTM) 33.76%
GM 88.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDMD Yearly Profit, Operating, Gross MarginsBDMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BDMD is creating value.
BDMD has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, BDMD has a worse debt to assets ratio.
BDMD Yearly Shares OutstandingBDMD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
BDMD Yearly Total Debt VS Total AssetsBDMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 3.08 indicates that BDMD is not in any danger for bankruptcy at the moment.
BDMD has a Altman-Z score of 3.08. This is in the better half of the industry: BDMD outperforms 69.63% of its industry peers.
A Debt/Equity ratio of 0.49 indicates that BDMD is not too dependend on debt financing.
BDMD has a Debt to Equity ratio (0.49) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z 3.08
ROIC/WACC3.43
WACC6.6%
BDMD Yearly LT Debt VS Equity VS FCFBDMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.77 indicates that BDMD should not have too much problems paying its short term obligations.
With a Current ratio value of 1.77, BDMD is not doing good in the industry: 68.59% of the companies in the same industry are doing better.
BDMD has a Quick Ratio of 1.74. This is a normal value and indicates that BDMD is financially healthy and should not expect problems in meeting its short term obligations.
BDMD's Quick ratio of 1.74 is in line compared to the rest of the industry. BDMD outperforms 47.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.74
BDMD Yearly Current Assets VS Current LiabilitesBDMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.58% over the past year.
Looking at the last year, BDMD shows a quite strong growth in Revenue. The Revenue has grown by 17.74% in the last year.
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.58%
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDMD Yearly Revenue VS EstimatesBDMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 10M 20M 30M

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 5.10, the valuation of BDMD can be described as very cheap.
Based on the Price/Earnings ratio, BDMD is valued cheaply inside the industry as 97.38% of the companies are valued more expensively.
BDMD is valuated cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 5.1
Fwd PE N/A
BDMD Price Earnings VS Forward Price EarningsBDMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

BDMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BDMD is cheaper than 98.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.8
BDMD Per share dataBDMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BDMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BAIRD MEDICAL INVESTMENT HOL

NASDAQ:BDMD (9/12/2025, 8:00:01 PM)

2.45

-0.05 (-2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-15 2025-05-15
Earnings (Next)N/A N/A
Inst Owners1.4%
Inst Owner ChangeN/A
Ins Owners71.59%
Ins Owner ChangeN/A
Market Cap62.62M
AnalystsN/A
Price TargetN/A
Short Float %445.08%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 5.1
Fwd PE N/A
P/S 1.69
P/FCF N/A
P/OCF N/A
P/B 1.58
P/tB 1.58
EV/EBITDA 3.8
EPS(TTM)0.48
EY19.59%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS1.45
BVpS1.55
TBVpS1.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 16.04%
ROE 31.53%
ROCE 35.34%
ROIC 22.61%
ROICexc 23.79%
ROICexgc 23.82%
OM 41.35%
PM (TTM) 33.76%
GM 88.17%
FCFM N/A
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA 1.17
Cap/Depr 189.31%
Cap/Sales 7.7%
Interest Coverage 30.8
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.77
Quick Ratio 1.74
Altman-Z 3.08
F-Score3
WACC6.6%
ROIC/WACC3.43
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.58%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-150.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-518.93%
OCF growth 3YN/A
OCF growth 5YN/A